1 day Ago By ABMN Staff
Renaissance Technologies LLC boosted its position in shares of Lineage Cell Therapeutics, Inc. ( NYSEAMERICAN:LCTX – Free Report ) by 1,058.3% in the fourth quarter, Holdings Channel reports.
The fund owned 2,283,072 shares of the company’s stock after acquiring an additional 2,085,972 shares during the period. Renaissance Technologies LLC’s holdings in Lineage Cell Therapeutics were worth $1,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other hedge funds also recently bought and sold shares of the company.
State Street Corp boosted its position in shares of Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after acquiring an additional 45,483 shares during the period.
Barclays PLC grew its position in Lineage Cell Therapeutics by 311.3% in the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after purchasing an additional 159,924 shares during the last quarter.
Geode Capital Management LLC grew its position in Lineage Cell Therapeutics by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock worth $3,331,000 after purchasing an additional 83,274 shares during the last quarter.
JPMorgan Chase & Co. raised its position in shares of Lineage Cell Therapeutics by 13.9% during the third quarter.
JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock valued at $613,000 after buying an additional 82,864 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Lineage Cell Therapeutics by 35.
5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after buying an additional 18,053 shares during the period. 62.
47% of the stock is currently owned by institutional investors. Lineage Cell Therapeutics Price Performance Lineage Cell Therapeutics stock opened at $0.47 on Wednesday.
The firm has a market capitalization of $103.82 million, a P/E ratio of -3.93 and a beta of 1.
21. The stock has a fifty day moving average price of $0.50 and a two-hundred day moving average price of $0.
65. Lineage Cell Therapeutics, Inc. has a 52-week low of $0.
37 and a 52-week high of $1.40. Wall Street Analysts Forecast Growth Get Our Latest Stock Analysis on Lineage Cell Therapeutics Lineage Cell Therapeutics Company Profile ( Free Report ) Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.
The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. Recommended Stories Want to see what other hedge funds are holding LCTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lineage Cell Therapeutics, Inc.
( NYSEAMERICAN:LCTX – Free Report ). Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
